Table 1 Baseline characteristics of patients in the calibration cohort with ulcerative colitis according to one-year treatment outcome level
Patients groups | Mild N = 23 | Moderate N = 18 | Severe N = 25 |
|---|---|---|---|
Age med (IQR) | 41 (35–54) | 35 (24–55) | 41 (27–54) |
Sex | |||
Female | 15 (65%) | 7 (39%) | 9 (36%) |
Male | 8 (35%) | 11 (61%) | 16 (64%) |
Colonic area involved | |||
Proctitis | 9 (39%) | 3 (17%) | 3 (12%) |
Left side | 9 (39%) | 7 (39%) | 10 (40%) |
Extensive | 5 (22%) | 8 (44%) | 12 (48%) |
Smoking | 14 | 21 | 12 |
Current smoker | 4 (29%) | 2 (17%) | 2 (10%) |
Non-smoker | 10 (71%) | 10 (83%) | 18 (90%) |
Mucosal TNF* | 10,500 (4600–11,900) | 12,000 (8000–17,200) | 26,900 (18700–40,400) |
UCDAI med (IQR)* at debut | 7 (5–8) | 9 (8–12) | 12 (9–12) |
Calprotectin med (IQR) | 590 (400–1100) | 790 (470–1540) | 2300 (670–2500) |
RHI med (IQR) | 9 (5–10) | 7 (6–10) | 9 (7–12) |
UCCS score 1-year med (IQR) | 0 (0–0) | 0 (0–2) | 0 (0–2) |
Calprotectin 1-year med (IQR) | 60 (25–85) | 50 (25–100) | 25 (0–160) |